瘤的乙酸盐依赖性是瘤的依赖性
Sarah A Comerford1, Zhiguang Huang2, Xinlin Du2
1Department of Molecular Genetics, UT Southwestern Medical Center, Dallas, TX 75390, USA.
Cell
|December 20, 2014
概括
酶ACSS2 (乙-CoA合成酶2) 通过使用乙酸盐帮助瘤生长. 阻止ACSS2显著减少了小鼠的瘤大小,这表明它.
科学领域:
- 生物化学 生物化学
- 代谢途径 代谢途径
- 癌症生物学 癌症生物学
背景情况:
- 乙-CoA (AcCoA) 对于细胞能量,生长和基因调节至关重要.
- 高糖解或缺氧的瘤依赖AcCoA生存.
- ACSS2是AcCoA代谢中的一个关键酶.
研究的目的:
- 研究核细胞酸乙-CoA合成酶 (ACSS2) 在瘤代谢中的作用.
- 为了确定ACSS2是否是癌症的潜在治疗点.
主要方法:
- 使用缺乏ACSS2酶的小鼠.
- 在两种肝细胞癌模型中评估了瘤负担.
- 测量了细胞酸盐的吸收和纳入脂质和组织蛋白的过程.
主要成果:
- 缺乏ACSS2的小鼠显示,瘤负担显著降低.
- ACSS2活动占了细胞酸盐吸收的大部分.
- 人类瘤中很大一部分表达了ACSS2.
结论:
- ACSS2是使用乙酸盐治疗瘤的AcCoA的关键来源.
- 在广泛的瘤中,ACSS2代表了可向的代谢脆弱性.
- 准ACSS2可能为癌症治疗提供一种新的治疗策略.
相关概念视频
Adaptive Mechanisms in Cancer Cells
7.6K
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
7.6K
Electron Transport Chain: Complex I and II
19.8K
The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
ROS generation is regulated and maintained at moderate levels necessary...
19.8K
Phase II Reactions: Acetylation Reactions
1.1K
Acetylation, a phase II biotransformation reaction, introduces an acetyl group to drugs or their metabolites. Acetyltransferase enzymes facilitate this reaction, which resembles α-amino acid conjugation due to the addition of a functional group to the drug molecule.
The substrates for acetylation are typically drugs or their metabolites with an amino, sulfonamide, or hydrazine functional group. Acetylation can occur at several points in the drug molecule, including primary, secondary, and...
The substrates for acetylation are typically drugs or their metabolites with an amino, sulfonamide, or hydrazine functional group. Acetylation can occur at several points in the drug molecule, including primary, secondary, and...
1.1K
Allosteric Proteins-ATCase
7.0K
Binding sites linkages can regulate a protein's function. For example, enzyme activity is often regulated through a feedback mechanism where the end product of the biochemical process serves as an inhibitor.
Aspartate transcarbamoylase (ATCase) is a cytosolic enzyme that catalyzes the condensation of L-aspartate and carbamoyl phosphate to N-carbamoyl-L-aspartate. This reaction is the first step in pyrimidine biosynthesis. UTP and CTP, the end products of the pyrimidine synthesis...
Aspartate transcarbamoylase (ATCase) is a cytosolic enzyme that catalyzes the condensation of L-aspartate and carbamoyl phosphate to N-carbamoyl-L-aspartate. This reaction is the first step in pyrimidine biosynthesis. UTP and CTP, the end products of the pyrimidine synthesis...
7.0K
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
74
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
74
Treatment Resistant Cancers
3.9K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.9K


